In this study, we describe the characterization of an infrequently encountered class A carbapenemase, IMI-1, from a clinical Enterobacter cloacae isolate. The isolate had high levels of resistance to carbapenems but retained susceptibility to expanded-spectrum cephalosporins. The bla IMI-1 gene was chromosomally encoded. Detection of the IMI-1 producer highlights the diversity of carbapenemases in a local clinical setting.
The emergence and dissemination of carbapenemaseproducing Enterobacteriaceae is an escalating global threat. As a result of national surveillance efforts for carbapenemnonsusceptible clinical Enterobacteriaceae isolates, we detected an Enterobacter cloacae isolate carrying an unusual class A carbapenemase, IMI-1. Here, we describe its characteristics.
In June 2012, a 68-year-old male with diffuse large B cell lymphoma was admitted. Chemotherapy was initiated, and he developed neutropenic sepsis 7 days later. Wound discharge cultures yielded a carbapenem-resistant Enterobacter cloacae with the same antibiogram from two consecutive cultures. As growth of the organism was pure and heavy and it was isolated on repeat culture, this was deemed an infection. Subsequent wound swab cultures grew a multidrug-resistant Acinetobacter baumannii. During hospitalization, he had extensive antibiotic exposure including amoxicillin/clavulanic acid, piperacillin/tazobactam, meropenem, vancomycin, ciprofloxacin, levofloxacin, co-trimoxazole and caspofungin. He did not have a history of travel abroad. The patient died in July 2012 due to complications secondary to infection with carbapenem-resistant Enterobacter cloacae and multi-drug resistant A. baumannii.
The Enterobacter cloacae isolate, designated ENT209, was submitted to the National Public Health Laboratory (NPHL), Singapore, for further workup as part of the national surveillance programme. Species identification was made using matrix-assisted laser desorption ionization-time of flight-mass spectrometer (Bruker Daltonics). MIC values were initially measured by the Vitek 2 automated system (bioMérieux) using AST-GN48 Gram-negative cards for antimicrobial susceptibility testing. At the NPHL, MICs were reconfirmed by Etest (bioMérieux), with susceptibility defined according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints. The isolate was resistant to ampicillin, cefoxitin and carbapenems but sensitive to expanded-spectrum cephalosporins (cefotaxime and ceftazidime) and aztreonam. The isolate was also sensitive to fluoroquinolones (ciprofloxacin and levofloxacin), aminoglycosides (amikacin and gentamicin), colistin and tigecycline (Table 1) .
Phenotypic screening using diagnostic tablets to identify Klebsiella pneumoniae carbapenemases and metallo-b-lactamases (KPC+MBL Confirm ID kit, Rosco Diagnostica) demonstrated marked synergy with meropenem+boronic acid discs, indicating the presence of a class A carbapenemase. The isolate was negative for bla KPC-type by PCR (Teo et al., 2012) . Further PCR analysis was performed for the detection of bla GES-type and bla IMI-type (Teo et al., 2012) , and the isolate was found to be bla IMI-type positive. Fulllength gene sequencing using the following primers (59-ATGTCACTTAATGTAAAACC-39 and 59-TTATTTAAGG-TTATCAATTGC-39) revealed 100 % identity to bla IMI-1 (GenBank accession number U50278).
The isolate underwent PCR screening for other transmissible b-lactamases, including MBLs (NDM-1, VIM-type, IMP-type), extended spectrum b-lactamases (TEM-type, SHV-type, CTX-M-type) (Teo et al., 2012) and oxacillinases (Woodford et al., 2006) . The isolate was negative for TEM-type, SHV-type, CTX-M-type and oxacillinases.
Conjugation experiments were performed to assess the transferability of bla IMI-1 from Enterobacter cloacae to drugsusceptible, azide-resistant recipient Escherichia coli J53. Transconjugants were selected on LB agar containing sodium azide (80 mg l 21 ) and ampicillin (50 mg l
21
); however, no transconjugants were obtained, indicating that bla IMI-1 was not transmissible.
The presence of plasmids from Enterobacter cloacae ENT 209 was analysed by S1 nuclease digestion of whole genomic DNA followed by pulsed field gel electrophoresis (S1-PFGE) (Barton et al., 1995) as well as extractions made with QIAprep Spin Miniprep kit (Qiagen). No plasmids could be visualized upon electrophoresis.
Pulsed field gel electrophoresis (PFGE) of Enterobacter cloacae ENT 209 genomic DNA was prepared in agarose blocks and digested with the restriction enzyme XbaI. The DNA fragments were separated by use of a CHEFMapper XA PFGE system (Bio-Rad) for 20 h at 6 V cm 21 and 14 u C, with a pulse angle of 120 u and pulse times from 5 to 20 s. Southern hybridization analysis was performed on the PFGE-separated genomic DNA using a 238 bp DIG-labelled probe amplified from bla IMI-1 using primers IMI-F 59-TCGGTGGTCCTGAGGGTATGACT-39 and IMI-R 59-ATACGCGCTGCACCGGTTGT-39. The bla IMI-1 specific probe hybridized to a 23 kb chromosomal fragment.
The widespread dissemination of carbapenem-resistant Enterobacteriaceae has increased in the last decade, largely due to acquired beta-lactamase genes encoding carbapenemases. Among the class A carbapenemases, KPC is prevalent (Nordmann et al., 2011) , whereas IMI enzymes have been infrequently described. The bla IMI-1 gene is located in the chromosome of Enterobacter cloacae (Rasmussen et al., 1996) , whereas bla IMI-2 and bla IMI-3 are plasmid-located and have been detected in Enterobacter spp. and E. coli (Aubron et al., 2005; Chu et al., 2011; RojoBezares et al., 2012) . IMI-1 has a characteristic hydrolytic profile. Expanded-spectrum cephalosporins are poor substrates for IMI-1; however, carbapenems are efficiently hydrolysed (Rasmussen et al., 1996) . This is reflected in the susceptibility profile of IMI-1 E. cloacae producers, with sensitivity towards third-generation cephalosporins but resistance towards carbapenems (Table 1) . This is the first instance of bla IMI-1 being detected in clinical isolates in Singapore. Apart from the initial description of IMI-1 from Enterobacter cloacae isolates (Rasmussen et al., 1996) and another recent report from France (Naas et al., 2012) , there appears to be no other clinical report.
As previously described, bla IMI-1 in this isolate was also found to be chromosomally encoded (Rasmussen et al., 1996; Naas et al., 2012) . In our hands, the determinant was nontransmissible by conjugation, which probably accounts for the fact that they are not well disseminated. Extendedspectrum b-lactamases and oxacillinases were absent from the isolate, supporting the antibiotic susceptibility profile of cephalosporin sensitivity. The isolate was submitted to Rasmussen et al. (1996) and Naas et al. (2012) , respectively. DFull MICs were not available, but the authors indicate that the isolate was resistant to penicillins and sensitive to expanded-spectrum cephalosporins, aminoglycosides and quinolones (Naas et al., 2012) .
the NPHL as part of a nationwide surveillance programme for carbapenem nonsusceptible Enterobacteriaceae. The programme has been running since September 2010, and 183 carbapenem nonsusceptible clinical isolates were screened (of these 25 were Enterobacter cloacae and 3 were Enterobacter aerogenes) before detecting this bla IMI-1 -positive isolate. Although it is an infrequently encountered mechanism of carbapenem resistance; nonetheless, this study highlights the diverse range of carbapenemaseproducers that can surface in the clinical setting.
